非布司他联合前列地尔对慢性肾脏病患者肾功能及血尿酸eGFR的影响

doi:10.3969/j.issn.1006-6233.2022.03.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1229 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effects of febuxostat combined with alprostadil on renal function, serum uric acid and Gglomerular filtration rate (eGFR) in patients with chronic kidney disease. Methods: A total of 103 patients with chronic kidney disease who received treatment in our hospital from January 2018 to January 2021 were selected and divided into combination group (n=52) and monotherapy group (n=51) by simple random grouping method. The monotherapy group was treated with alprostadil, and the combination group was treated with febuxostat on the basis of the monotherapy group. The clinical efficacy, serum uric acid, eGFR, serum creatinine (Scr), urea nitrogen (BUN), 24-hour urine protein level and the incidence of adverse reactions were compared between the two groups. Results: After treatment, there was statistical difference in the total effective rate between the two groups (P<0.05). Before treatment, there was no significant difference in renal function between the combination group and the monotherapy group. After treatment, Scr, BUN and 24-hour urine protein quantification were significantly decreased in both groups, and the combination group was lower than the monotherapy group; the difference was statistically significant (P<0.05). Before treatment, there was no significant difference in serum uric acid and eGFR between the two groups. After treatment, serum uric acid was significantly decreased in both groups, and eGFR was significantly increased in the combination group compared with the monotherapy group, with statistical significance (P<0.05). The total incidence of adverse reactions between the two groups was 5.77% and 15.69%, with no statistical significance (P>0.05). Conclusion: In patients with chronic kidney disease, febuxostat combined with aprostadil has a significant therapeutic effect, which can effectively improve the renal function and serum uric acid and eGFR levels.

Key words： Chronic kidney disease Febuxostat Alprostadil Renal function Blood uric acid Glomerular filtration rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.03.030 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I3/494

[1] 李金萍,齐平平,胡楠,等.高钾血症对慢性肾脏病3~5期未透析患者肾功能进展的影响[J].中华医学杂志,2021,101(18):1363~1368.
[2] 谭昭,李文歌.非布司他治疗慢性肾脏病合并高尿酸血症患者的肾脏保护作用:一项随机对照研究[J].福建医科大学学报,2019,53(1):32~37.
[3] 沈杰,叶朝阳.前列地尔联合杏丁注射液治疗慢性肾衰竭的效果及对Hcy,FGF-23水平的影响[J].现代医学,2019,47(1):45~49.
[4] 咸伟,董吉,周朝阳.非布司他治疗慢性肾病伴高尿酸血症的疗效和机制分析[J].药物评价研究,2019,42(3):154~157.
[5] 肾脏病相关专家小组(统称).上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28~34.
[6] 杨雄,高伟,邱万胜,等.白蛋白球蛋白比值对慢性肾脏病患者预后判断的价值研究[J].陕西医学杂志,2020,49(6):728~731.
[7] 马媛媛,穆红光,王晓寅,等.尿毒清颗粒联合非布司他治疗慢性肾病的疗效观察[J].河北医药,2020,42(12):111~114.
[8] 李友福,罗雪梅,方文.前列地尔联合肾康注射液治疗老年慢性肾脏疾病的疗效观察[J].西部中医药,2019,32(6):89~91.
[9] 王鑫,高弼虎,张亚男,等.别嘌醇联合非布司他对高尿酸慢性肾病患者尿酸水平及肾功能的影响[J].中国临床药理学杂志,2019,35(18):2040~2042,2050.
[10] 李旭涵,陈欣,谌达程,等.肾功能对慢性肾脏病血清游离轻链的影响[J].肾脏病与透析肾移植杂志,2019,28(2):113~118.
[11] 李青华,谢海英,包国祥,等.慢性肾脏病患者各期肱踝脉搏波传导速度与肾小球滤过率及相关影响因素分析[J].临床心血管病杂志,2018,34(11):51~54.
[12] 宋柳全,谭焕原,谢宝超,等.非布司他在慢性肾脏病合并高尿酸血症治疗中的应用价值分析[J].山东医药,2019,59(14):60~62.